Preston et al. have demonstrated that the expression of RIPK3 was inhibited or not detected in MASH patients and human primary hepatocytes exposed to RIPK3 inducers (Preston et al., 2022). The gene discussed is RIPK3; the disease is metabolic dysfunction-associated steatohepatitis.